Literature DB >> 11457734

PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells.

C M van Golen1, T S Schwab, K M Ignatoski, S P Ethier, E L Feldman.   

Abstract

Insulin-like growth factor I (IGF-I) protects cells from apoptosis primarily through the action of phosphatidylinositol-3 kinase and the downstream serine/threonine kinase Akt. The PTEN gene product, a protein which dephosphorylates phosphatidylinositol lipids, prevents activation of Akt and regulates several cellular functions, including cell cycle progression, cell migration, and survival from apoptosis. In this study, PTEN overexpression decreases IGF-I-induced Akt activity, enhances serum withdrawal-induced apoptosis, and decreases IGF-I protection and cell growth in SHEP cells. The PTEN lipid phosphatase mutant G129E fails to inhibit IGF-I-stimulated Akt activity and protection from apoptosis. The C124S mutation, which abolishes both lipid and protein phosphatase activity, fails to inhibit Akt activity and IGF-I protection against hyperosmotic-induced apoptosis but still inhibits growth and IGF-I protection against serum withdrawal-induced apoptosis. These data suggest a role for PTEN in modulating the effect of IGF-I on Akt activity, neuroblastoma cell growth, and protection against apoptotic stimuli.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457734

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  Inhibition of neuronal phenotype by PTEN in PC12 cells.

Authors:  Sergei Musatov; Jill Roberts; Andrew I Brooks; John Pena; Simone Betchen; Donald W Pfaff; Michael G Kaplitt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-27       Impact factor: 11.205

Review 2.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

Review 3.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

4.  Anti-angiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation.

Authors:  Ki Young Kim; Jin Hee Ahn; Hyae Gyeong Cheon
Journal:  Mol Cell Biochem       Date:  2011-07-17       Impact factor: 3.396

5.  Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation.

Authors:  Juinn-Lin Liu; Xiaoyang Sheng; Zsuzsanna K Hortobagyi; Zhenyu Mao; Gary E Gallick; W K Alfred Yung
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 6.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

7.  Integrin expression regulates neuroblastoma attachment and migration.

Authors:  Amy Meyer; Cynthia M van Golen; Bhumsoo Kim; Kenneth L van Golen; Eva L Feldman
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 8.  The Role of PI3K/Akt and ERK in Neurodegenerative Disorders.

Authors:  Sachchida Nand Rai; Hagera Dilnashin; Hareram Birla; Saumitra Sen Singh; Walia Zahra; Aaina Singh Rathore; Brijesh Kumar Singh; Surya Pratap Singh
Journal:  Neurotox Res       Date:  2019-02-01       Impact factor: 3.911

9.  Patterning N-type and S-type neuroblastoma cells with Pluronic F108 and ECM proteins.

Authors:  Joseph M Corey; Caitlyn C Gertz; Thomas J Sutton; Qiaoran Chen; Katherine B Mycek; Bor-Shuen Wang; Abbey A Martin; Sara L Johnson; Eva L Feldman
Journal:  J Biomed Mater Res A       Date:  2010-05       Impact factor: 4.396

10.  Insulin receptor substrate (IRS)-2, not IRS-1, protects human neuroblastoma cells against apoptosis.

Authors:  Bhumsoo Kim; Eva L Feldman
Journal:  Apoptosis       Date:  2009-05       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.